160 related articles for article (PubMed ID: 34782263)
1. Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.
Lyou Y; Rosenberg JE; Hoffman-Censits J; Quinn DI; Petrylak D; Galsky M; Vaishampayan U; De Giorgi U; Gupta S; Burris H; Rearden J; Li A; Xu C; Andresen C; Moran S; Daneshmand S; Bajorin D; Pal SK; Grivas P
Clin Genitourin Cancer; 2022 Feb; 20(1):35-42. PubMed ID: 34782263
[TBL] [Abstract][Full Text] [Related]
2. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
Lyou Y; Grivas P; Rosenberg JE; Hoffman-Censits J; Quinn DI; P Petrylak D; Galsky M; Vaishampayan U; De Giorgi U; Gupta S; Burris H; Rearden J; Li A; Wang H; Reyes M; Moran S; Daneshmand S; Bajorin D; Pal SK
Eur Urol; 2020 Dec; 78(6):916-924. PubMed ID: 32847703
[TBL] [Abstract][Full Text] [Related]
3. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Pal SK; Bajorin D; Dizman N; Hoffman-Censits J; Quinn DI; Petrylak DP; Galsky MD; Vaishampayan U; De Giorgi U; Gupta S; Burris HA; Soifer HS; Li G; Wang H; Dambkowski CL; Moran S; Daneshmand S; Rosenberg JE
Cancer; 2020 Jun; 126(11):2597-2606. PubMed ID: 32208524
[TBL] [Abstract][Full Text] [Related]
4. Targeting
Pal SK; Somford DM; Grivas P; Sridhar SS; Gupta S; Bellmunt J; Sonpavde G; Fleming MT; Lerner SP; Loriot Y; Hoffman-Censits J; Valderrama BP; Andresen C; Schnabel MJ; Cole S; Daneshmand S
Future Oncol; 2022 Jul; 18(21):2599-2614. PubMed ID: 35608106
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
[TBL] [Abstract][Full Text] [Related]
6. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
[TBL] [Abstract][Full Text] [Related]
7. Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
Li H; Ni M; Xue C; Li L; Huang R; Yang W; Hu A; An X; Shi Y
Clin Immunol; 2022 Mar; 236():108927. PubMed ID: 35031491
[TBL] [Abstract][Full Text] [Related]
8. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
Necchi A; Pouessel D; Leibowitz R; Gupta S; Fléchon A; García-Donas J; Bilen MA; Debruyne PR; Milowsky MI; Friedlander T; Maio M; Gilmartin A; Li X; Veronese ML; Loriot Y
Ann Oncol; 2024 Feb; 35(2):200-210. PubMed ID: 37956738
[TBL] [Abstract][Full Text] [Related]
9. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman AB; Sepúlveda-Sánchez JM; Cloughesy TF; Gil-Gil MJ; Puduvalli VK; Raizer JJ; De Vos FYF; Wen PY; Butowski NA; Clement PMJ; Groves MD; Belda-Iniesta C; Giglio P; Soifer HS; Rowsey S; Xu C; Avogadri F; Wei G; Moran S; Roth P
Clin Cancer Res; 2022 Jun; 28(11):2270-2277. PubMed ID: 35344029
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
12. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
Raggi D; Miceli R; Sonpavde G; Giannatempo P; Mariani L; Galsky MD; Bellmunt J; Necchi A
Ann Oncol; 2016 Jan; 27(1):49-61. PubMed ID: 26487582
[TBL] [Abstract][Full Text] [Related]
13. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
[TBL] [Abstract][Full Text] [Related]
14. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
[TBL] [Abstract][Full Text] [Related]
15. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Necchi A; Ramlau R; Falcón González A; Chaudhry A; Todenhöfer T; Tahbaz R; Fontana E; Giannatempo P; Deville JL; Pouessel D; Yoon S; Powles T; Bernat M; Häckl M; Marszewska M; McKernan P; Saulay M; Scaleia F; Engelhardt M; Loriot Y; Siefker-Radtke A; De Santis M
JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38627238
[TBL] [Abstract][Full Text] [Related]
16. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
Bellmunt J; Lalani AA; Jacobus S; Wankowicz SA; Polacek L; Takeda DY; Harshman LC; Wagle N; Moreno I; Lundgren K; Bossé D; Van Allen EM; Choueiri TK; Rosenberg JE
Br J Cancer; 2018 Sep; 119(6):707-712. PubMed ID: 30220708
[TBL] [Abstract][Full Text] [Related]
17. Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
Qu YY; Sun Z; Han W; Zou Q; Xing N; Luo H; Zhang X; He C; Bian XJ; Cai J; Chen C; Wang Q; Ye DW
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35537782
[TBL] [Abstract][Full Text] [Related]
18. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on
Sternberg CN; Petrylak DP; Bellmunt J; Nishiyama H; Necchi A; Gurney H; Lee JL; van der Heijden MS; Rosenbaum E; Penel N; Pang ST; Li JR; García Del Muro X; Joly F; Pápai Z; Bao W; Ellinghaus P; Lu C; Sierecki M; Coppieters S; Nakajima K; Ishida TC; Quinn DI
J Clin Oncol; 2023 Jan; 41(3):629-639. PubMed ID: 36240478
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Meynard L; Dinart D; Delaunay B; Fléchon A; Saldana C; Lefort F; Gravis G; Thiery-Vuillemin A; Cancel M; Coquan E; Ladoire S; Maillet D; Rolland F; Boughalem E; Martin S; Laramas M; Crouzet L; Abbar B; Falkowski S; Pouessel D; Roubaud G
Eur J Cancer; 2022 Nov; 175():43-53. PubMed ID: 36088671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]